| Daniel C Dahl, MD | |
|
700 19th St S, Bvamc, Birmingham, AL 35233-1927 | |
| (205) 933-8101 | |
| Not Available |
| Full Name | Daniel C Dahl |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 700 19th St S, Birmingham, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578506788 | NPI | - | NPPES |
| 330500518 | Other | AL | MEDICAID REHAB |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 13802 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Daniel C Dahl, MD 700 19th St S, Bvamc, Birmingham, AL 35233-1927 Ph: (205) 933-8101 | Daniel C Dahl, MD 700 19th St S, Bvamc, Birmingham, AL 35233-1927 Ph: (205) 933-8101 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.
Researchers have found that California high school students eat less fat and sugar and fewer calories at school than their peers in states that allow the sale of snacks with more of those.
Led by biomedical engineer Justin Zook of the National Institute of Standards and Technology, a team of scientists from Harvard University and the Virginia Bioinformatics Institute of Virginia Tech has presented new methods to integrate data from different sequencing platforms, thus producing a reliable set of genotypes to benchmark human genome sequencing.
A paper published in the current issue of Science has challenged beliefs about the role of dopamine in the brain, which could lead to new treatments for Parkinson's disease, schizophrenia and drug addiction. The research suggests that dopamine has a far wider, less specialised role than previously hypothesised.
› Verified 2 days ago
Rayford W Thweatt, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Marla B Morgan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Robins J Newton, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2700 10th Ave S Ste 400, Birmingham, AL 35205 Phone: 205-918-0507 Fax: 205-930-2716 | |
Mohamed Kazamel, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Dr. Rodney K Swillie, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3686 Grandview Pkwy Ste 600, Birmingham, AL 35243 Phone: 205-971-3600 Fax: 844-772-0468 | |
Sandra L Frazier, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 619 19t Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Michael Alonzo Lopez, M.D., PH.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1600 6th Ave S # Chb314, Birmingham, AL 35233 Phone: 205-996-7850 |